van Dalen EC, Raphael MF, Caron HN, Kremer LCM. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev. 2014:CD006647. https://doi.org/10.1002/14651858.CD006647.pub4.
Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer. 2005;44:600–6. https://doi.org/10.1002/pbc.20352.
Article
PubMed
Google Scholar
Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–15. https://doi.org/10.1056/NEJM199103213241205.
Article
CAS
PubMed
Google Scholar
von Hoff DD, Layard MW, Basa P, Davis HL, von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7. https://doi.org/10.7326/0003-4819-91-5-710.
Article
Google Scholar
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869–79. https://doi.org/10.1002/cncr.11407.
Article
CAS
Google Scholar
van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011:CD003917. https://doi.org/10.1002/14651858.CD003917.pub4.
van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010:CD005006. https://doi.org/10.1002/14651858.CD005006.pub4.
Bielack SS, Erttmann R, Kempf-Bielack B, Winkler K. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer. 1996;32:1652–60. https://doi.org/10.1016/0959-8049(96)00177-3.
Article
Google Scholar
Robert J. Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration? Cancer Drug Deliv. 1987;4:191–9.
Article
CAS
Google Scholar
van Dalen EC, van der Pal HJH, Kremer LCM. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2016;3:CD005008. https://doi.org/10.1002/14651858.CD005008.pub4.
Article
PubMed
Google Scholar
Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: the memorial Sloan-Kettering-New York-II protocol. Cancer. 1993;72:3120–30. https://doi.org/10.1002/1097-0142(19931115)72:10<3120::AID-CNCR2820721038>3.0.CO;2-Q.
Article
CAS
PubMed
Google Scholar
Escherich G, Göbel U, Jorch N, Spaar HJ, Janka-Schaub GE. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia. Klin Padiatr. 2007;219:134–8. https://doi.org/10.1055/s-2007-973849.
Article
CAS
PubMed
Google Scholar
Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, et al. Doxorubicin administration by continuous infusion is not Cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol. 2002;20:1677–82. https://doi.org/10.1200/JCO.2002.20.6.1677.
Article
CAS
PubMed
Google Scholar
Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, et al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics. 2012;130:1003–11. https://doi.org/10.1542/peds.2012-0727.
Article
PubMed
PubMed Central
Google Scholar
Völler S, Boos J, Krischke M, Würthwein G, Kontny NE, Boddy AV, et al. Age-dependent pharmacokinetics of doxorubicin in children with cancer. Clin Pharmacokinet. 2015;54:1139–49. https://doi.org/10.1007/s40262-015-0272-4.
Article
CAS
PubMed
Google Scholar
Völler S, Hempel G, Würthwein G, Boddy AV, Krischke M, Andre N, et al. Towards a model-based dose recommendation for doxorubicin in children. Clin Pharmacokinet. 2017;56:215–23. https://doi.org/10.1007/s40262-016-0451-y.
Article
CAS
PubMed
Google Scholar
Balis FM, Womer RB, Berg S, Winick N, Adamson PC, Fox E. Dosing anticancer drugs in infants: current approach and recommendations from the Children's oncology Group's chemotherapy standardization task force. Pediatr Blood Cancer. 2017. https://doi.org/10.1002/pbc.26636.
Article
Google Scholar
CDC. Centers for Disease Control and Prevention growth charts; 2010. https://www.cdc.gov/growthcharts/. Accessed 15 Feb 2019.
Google Scholar
Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503–12. https://doi.org/10.1007/BF01060893.
Article
CAS
PubMed
Google Scholar
EMEA. Guideline on the investigation of bioequivalence; 2010. https://www.ema.europa.eu/en/investigation-bioequivalence. Accessed 14 Feb 2019.
Google Scholar
Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM Users’s guides (1989–2009). Ellicott City: Icon Development Solutions; 2009.
Google Scholar
R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018.
Google Scholar
RStudio Team. RStudio: integrated development environment for R. Boston: RStudio, Inc.; 2016.
Google Scholar
Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study. J Natl Cancer Inst. 2008;100:1368–79. https://doi.org/10.1093/jnci/djn310.
Article
PubMed
PubMed Central
Google Scholar
Rössig C, Jürgens H, Schrappe M, Möricke A, Henze G, von Stackelberg A, et al. Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria. Pediatr Blood Cancer. 2013;60:1574–81. https://doi.org/10.1002/pbc.24598.
Article
PubMed
Google Scholar
Palle J, Frost B-M, Peterson C, Gustafsson G, Hellebostad M, Kanerva J, et al. Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs. 2006;17:385–92. https://doi.org/10.1097/01.cad.0000198911.98442.16.
Article
CAS
PubMed
Google Scholar
Powell C. The Delphi technique: myths and realities. J Adv Nurs. 2003;41:376–82.
Article
Google Scholar
de Jonge ME, Huitema ADR, Schellens JHM, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation a review. Clin Pharmacokinet. 2005;44:147–73. https://doi.org/10.2165/00003088-200544020-00002.
Article
PubMed
Google Scholar
Thomas H, Boddy AV, English MW, Hobson R, Imeson J, Lewis I, et al. Prospective validation of renal function–based carboplatin dosing in children with cancer: a United Kingdom Children’s cancer study group trial. J Clin Oncol. 2000;18:3614–21. https://doi.org/10.1200/JCO.2000.18.21.3614.
Article
CAS
PubMed
Google Scholar
Loeffen EAH, van Dalen EC, Mulder RL, van de Wetering MD, Kremer LCM, Tissing WJE. The duration of anthracycline infusion should be at least one hour in children with cancer: a clinical practice guideline. Pediatr Blood Cancer. 2018. https://doi.org/10.1002/pbc.26867.
Article
Google Scholar
Kremer LCM, van Dalen EC, Offringa M, Voûte PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002;13:503–12. https://doi.org/10.1093/annonc/mdf118.
Article
CAS
PubMed
Google Scholar
EMEA. Guideline on reporting the results of population pharmacokinetic analyses; 2007. https://www.ema.europa.eu/en/reporting-results-population-pharmacokinetic-analyses. Accessed 15 Feb 2019.
Google Scholar
Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. BMC Med Res Methodol. 2005. https://doi.org/10.1186/1471-2288-5-37.
Jacquet J-M, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J, et al. Doxorubicin and doxorubicinol: intra-and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol. 1990;27:219–25.
Article
CAS
Google Scholar
Eksborg S, Strandler H-S, Edsmyr F, Näslund I, Tahvanainen P. Pharmacokinetic study of IV infusions of Adriamycin. Eur J Clin Pharmacol. 1985;28:205–12.
Article
CAS
Google Scholar
Frost B-M, Eksborg S, Björk O, Abrahamsson J, Behrendtz M, Castor A, et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol. 2002;38:329–37. https://doi.org/10.1002/mpo.10052.
Article
PubMed
Google Scholar
Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338:499–505. https://doi.org/10.1056/NEJM199802193380803.
Article
CAS
PubMed
Google Scholar
Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2099–105. https://doi.org/10.1200/JCO.2007.13.3934.
Article
CAS
PubMed
Google Scholar
Hempel G, Flege S, Würthwein G, Boos J. Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2002;49:133–41. https://doi.org/10.1007/s00280-001-0392-4.
Article
CAS
PubMed
Google Scholar
Kontny NE, Wurthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, et al. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Cancer Chemother Pharmacol. 2013;71:749–63. https://doi.org/10.1007/s00280-013-2069-1.
Article
CAS
PubMed
Google Scholar
Bardin C, Veal G, Paci A, Chatelut E, Astier A, Levêque D, et al. Therapeutic drug monitoring in cancer--are we missing a trick? Eur J Cancer. 2014;50:2005–9. https://doi.org/10.1016/j.ejca.2014.04.013.
Article
CAS
PubMed
Google Scholar